PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65194-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)65194-7/fulltext
Section Title :
Section Order : 353
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65194-7&doi=10.1016/S1098-3015(10)65194-7
HEOR Topics :
Tags :
Regions :